Novartis Reports Seven New Tumor Cases in Zolgensma Patients

· Health · Switzerland

Novartis has confirmed that nine patients who received its spinal muscular atrophy gene therapy Zolgensma have developed tumors following treatment, with seven of those cases disclosed for the first time on Thursday. Two of the cases may be linked to the therapy, according to the company. Zolgensma is a one-time gene therapy for SMA, a rare and severe neuromuscular disease in children, and the new disclosures expand the known tumor signal among treated patients. The acknowledgment comes as regulators and clinicians closely track the long-term safety of gene therapies that use viral vectors to deliver genetic material.

Why it matters：Expanding tumor reports could reshape how regulators and physicians weigh the risk-benefit balance of viral-vector gene therapies and affect broader confidence in the field.

Key points

  • Nine Zolgensma recipients have developed tumors, seven of them newly disclosed.
  • Two of the cases may be linked to the treatment, Novartis said.
  • Zolgensma is a one-time gene therapy for spinal muscular atrophy in children.

Sources (original reporting)

More stories from this day